iBio, Inc. is a biopharmaceutical company focused on developing AI-powered precision antibody therapeutics. The company specializes in epitope-steering and antibody optimization, leveraging plant-based technologies to create novel products for treating serious infectious diseases. iBio's therapeutic pipeline targets obesity, cardiometabolic conditions, and immuno-oncology, with a focus on first-in-class and best-in-class molecules.
The company collaborates with partners to advance its preclinical pipeline and innovate solutions for challenging areas in oncology discovery and development. iBio offers licensing opportunities for its discovery platform and seeks partnerships to accelerate the development of hard-to-engineer antibodies. Through its AI-driven approach, iBio aims to rapidly advance therapeutic candidates for conditions such as obesity, diabetes, and heart disease.
